This content was funded by AstraZeneca, and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information, including Patient Information when making treatment decisions.
Indication and Usage
Capivasertib (TRUQAP®) in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Description
In this practical, case-based discussion, a breast oncology pharmacist and nurse practitioner walk through how they anticipate and manage the most common adverse events seen with capivasertib in HR-positive/HER2-negative advanced breast cancer.
Drawing on real-world clinic workflows, they share stepwise approaches to counseling, prophylaxis, and early intervention for diarrhea, rash, and hyperglycemia, including when to escalate monitoring or treatment and how to coordinate roles across the care team.
You’ll hear communication scripts, tips for using tools such as stool diaries and home glucometers, and strategies to keep patients on therapy safely and confidently.
Chapters
- 00:00 – 03:24 | Introduction
- 03:24 – 05:18 | When to consider capivasertib
- 05:18 – 08:51 | Introducing adverse events
- 08:51 – 16:18 | Diarrhea management
- 16:18 – 20:35 | Rash management
- 20:35 – 25:07 | Hyperglycemia management
- 25:07 – 27:31 | Care team best practices
- 27:31 – 31:18 | Top Tips & Takeaways
Speakers
Heather Moore1
Sarah Donohue2
1. Breast Oncology Pharmacist, Duke University Medical Center
2. Breast Oncology Nurse Practitioner, UCSF Health Breast Care Center
Select Safety Information About capivasertib (TRUQAP®) tablets
TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.
Serious adverse reactions include hyperglycemia, including diabetic ketoacidosis and fatal outcomes; diarrhea; and cutaneous adverse reactions. Monitor fasting glucose and hemoglobin A1C levels regularly. May cause fetal harm when administered to a pregnant woman. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), increased fasting glucose (37%), nausea and fatigue (35% each), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).
Please see full Prescribing Information, including Patient Information for TRUQAP.
